Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Gpnmb defines a phagocytic state of microglia linked to cell death in prion disease mouse model.

Nature communications·2026

Same author

Protocol of the interdisciplinary and intersectoral randomized controlled trial in Parkinson patients in a specialized network in Germany: the INSPIRE Trial.

Neurological research and practice·2026

Same author

Reduced plasma TIA-1: bridging established pathology and novel biomarker potential.

Alzheimer's research & therapy·2026

Same author

A distinct tau oligomer strain defines the molecular and proteomic landscape of rapidly progressive Alzheimer's disease.

Acta neuropathologica·2026

Same author

Detection of alpha-synuclein seeding activity in tear fluid in patients with Parkinson's disease.

NPJ Parkinson's disease·2026

Same author

Therapeutic Potential of Amyloid-β Interactors in Rapidly Progressive Alzheimer's Disease-An In Silico Study.

Molecular informatics·2026

Same journal

Ataxia Global Initiative recommend MRI end-points for clinical trials in ataxias.

Nature reviews. Neurology·2026

Same journal

Adaptive deep brain stimulation in Parkinson disease: clinical implementation and outlook.

Nature reviews. Neurology·2026

Same journal

Moving artificial intelligence from research to real-world clinical use in neurology.

Nature reviews. Neurology·2026

Same journal

Artificial intelligence in headache care.

Nature reviews. Neurology·2026

Same journal

Artificial intelligence could reshape research and care in disorders of consciousness.

Nature reviews. Neurology·2026

Same journal

Christina Kim: functional and biochemical mapping of neural circuits.

Nature reviews. Neurology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 15, 2026

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Immunotherapy in prion disease.

Yvonne Roettger¹, Yansheng Du, Michael Bacher

¹Department of Neurology, Philipps-University Marburg, Baldingerstrasse, 35043 Marburg, Germany.

Nature Reviews. Neurology

|December 19, 2012

Summary

This summary is machine-generated.

Immunotherapy shows promise for treating prion diseases by targeting misfolded proteins. Research in animal models suggests immunization can slow progression and extend lifespan, offering hope for human treatments.

More Related Videos

Detection of Abnormal Prion Protein by Immunohistochemistry

Detection of Abnormal Prion Protein by Immunohistochemistry

Published on: May 5, 2023

Adipose-Derived Mesenchymal Stromal Cells Co-Cultured with Primary Mixed Glia to Reduce Prion-Induced Inflammation

Adipose-Derived Mesenchymal Stromal Cells Co-Cultured with Primary Mixed Glia to Reduce Prion-Induced Inflammation

Published on: August 11, 2023

Related Experiment Videos

Last Updated: May 15, 2026

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Detection of Abnormal Prion Protein by Immunohistochemistry

Detection of Abnormal Prion Protein by Immunohistochemistry

Published on: May 5, 2023

Adipose-Derived Mesenchymal Stromal Cells Co-Cultured with Primary Mixed Glia to Reduce Prion-Induced Inflammation

Adipose-Derived Mesenchymal Stromal Cells Co-Cultured with Primary Mixed Glia to Reduce Prion-Induced Inflammation

Published on: August 11, 2023

Area of Science:

Neurodegenerative diseases
Immunology
Protein misfolding disorders

Background:

Transmissible spongiform encephalopathies (TSEs), or prion diseases, are fatal neurodegenerative conditions.
Pathological hallmark involves misfolded prion protein accumulation, preceding central nervous system involvement in some forms.
Current prion diseases lack effective therapies, necessitating novel treatment strategies.

Purpose of the Study:

To review evidence for immunotherapy in prion disease prevention and treatment.
To discuss the potential of antibody-based strategies for prion diseases.
To explore challenges and therapeutic prospects of immunotherapy.

Main Methods:

Review of existing literature on prion diseases and immunotherapy.
Analysis of studies involving immunization in animal models of prion disease.
Discussion of self-tolerance and adverse effects as challenges.

Main Results:

Immunization strategies have shown potential in slowing disease progression in animal models.
Increased lifespan has been observed in animal models following immunization.
Evidence suggests immunotherapy could be a viable approach for prion diseases.

Conclusions:

Antibody-based immunotherapy presents a potential therapeutic avenue for prion diseases.
Further research is needed to overcome challenges like self-tolerance for human application.
Immunotherapy offers hope for improved outcomes in patients with prion diseases.